Table 1.
Clinical, Endoscopic, and Laboratory Markers Pre-, During, and Post-COVID-19
| Variables | Pre-COVID -180 to -1 d |
COVID 0 to +30 d |
Post-COVID +31 to +210 d |
P value Pre vs Post |
|---|---|---|---|---|
| Clinical DAI, Avg (n) | .7397 | |||
| HBI | 4.7 (50) | 4.7 (21) | 4.9 (41) | .74 |
| PMS | 3.0 (25) | 4.8 (6) | 2.1 (19) | .24 |
| Endoscopic DAI, Avg (n) | ||||
| SES-CD | 7.2 (17) | 7 (1) | 8.9 (15) | .69 |
| MES | 1.5 (9) | 2 (1) | 1.7 (11) | .70 |
| Biomarkers, Avg (n) | ||||
| C-reactive protein | 1.2 (83) | 2.5 (15) | 1.3 (56) | .18 |
| ESR | 25 (63) | 25 (14) | 26 (44) | .95 |
| Hemoglobin | 12.8 (84) | 12.6 (26) | 13.2 (60) | .50 |
| Fecal calprotectin | 388 (44) | 522 (12) | 250 (40) | .20 |
| Active disease, n (%) | 49 (60) | 16 (55) | 38 (59) | .87 |
| Delayed/discontinued | 9 (69) | 5 (83) | 4 (40) | |
| COVID-19 GI symptoms | 20 (61) | 8 (39) | 20 (71) | |
| Need for surgery, n (%) | 3 (2.8) | 0 (0) | 2 (1.8) | .68 |
| Need for IBD hospitalization, n (%) | 6 (5.6) | 2 (1.7) | 7 (6.2) | > .99 |
| Medication change, n (%) | 53 (50) | 33 (28) | 45 (40) | .14 |
| Newly started | 42 (40) | 14 (12) | 36 (32) | |
| Steroid | 17 (16) | 4 (3.4) | 15 (13) | |
| Delayed | 2 (1.9) | 10 (8.5) | 5 (4.4) | |
| Discontinued | 20 (19) | 8 (6.8) | 15 (13) |
NOTE. Unpaired Mann-Whitney and paired Wilcoxon revealed no significant differences between pre- and post-COVID-19 clinical, endoscopic, and laboratory values. Fisher exact test was used to compare differences in patient number with active disease, need for surgery, hospitalization, or medication change.
DAI, disease activity index; ESR, erythrocyte sedimentation rate; GI, gastrointestinal; HBI, Harvey Bradshaw Index; IBD, inflammatory bowel disease; MES, Mayo Endoscopic Score; PMS, partial Mayo score; SES-CD, Simple Endoscopic Score-Crohn’s Disease.